Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]
Discontinued
Reference number: GID-TA10880
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer have been revised. It is anticipated that the appraisal will begin in mid-May 2024 when we will write to you about how you can get involved.